Today’s AI Top Pick: PODD

8/13/2026 · Recently Alerted GARP screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Recently Alerted GARPPODDBUY NOW8.8 / 108/13/2026

Insulet (PODD) is the cleanest multi-timeframe setup in the pool right now. Every forecast horizon on every timeframe is positive: 4h shows +70.9%/+74.4%/+92.9% short/mid/long, 1d shows +17.1%/+62.3%/+77.1%, and 1wk shows +8.9%/+45.0%/+68.5%. That kind of uniform positivity across 4h/1d/1wk is rare in this pool — most 'strong' names (APP, FUTU, NRG) have a red flag on the weekly. And the entry isn't chased: position_in_21bar_range is only 16.8% (4h), 34.6% (1d), and 7.5% (1wk), with a -29.8% weekly drawdown — you're buying into weakness, not strength. The fundamentals fully support the tape. Sales YoY of 29.41%, EPS growth next year of 18.77%, profit margin 12.29%, ROE 26.02%, PEG 0.81, and fwdPe 18.78 — a rare combination of durable growth AND reasonable valuation in the med-tech space. Analyst recom is 1.96 (buy) with 17.1% consensus upside (and target likely conservative given post-earnings reset). Bullish_prob is 1.0, near_term_bullish 0.6, fundamental_score 7.25. Critically, the news landmine check passes: Q2 2026 earnings just printed (Aug 12), Canaccord maintained Buy on Aug 6 (only trimmed target to $179 — still ~22% upside from $146.20), and a Yahoo piece explicitly calls PODD 'undervalued as market stays cautious.' No guidance cut, no legal issue, no dilution — the drawdown is post-earnings sector pressure, not a broken thesis. Compare that to APP (fresh 52-week low headline), OPFI (analyst forecast cuts), ONON (Raymond James downgrade), or SRAD (cut 2026 outlook) — those are the setups the news actively undercuts. Why today rather than wait: the weekly is already -29.8% from the high with position at 7.5% of range — the pullback is essentially done, and both mid- and long-horizon weekly forecasts are +45% and +68%. Waiting for a deeper pullback risks missing the base breakout while every forecast is aligned. This is a buy-into-weakness setup that the tape says has already turned.

Entry zone

$143.00–$148.50 (scale in around current $146.20; add on any dip to $140 support)

Stop loss

$132.00 (below the recent 1wk low; ~10% risk, aligns with a break of the base)

First target

$170.00 (~16% upside, near 1d mid-horizon forecast and Canaccord PT)

Longer target

$205–$215 (~40–47% upside, aligns with 1wk mid/long forecast of +45–68% and pre-drawdown levels)

Risks

Post-earnings drift lower: -11.09% over the 21-bar daily window and -29.79% on weekly show sellers still in control until momentum flips
Med-device sector has been under pressure (perfYtd -48.97%, perfYear -53.15%) — sector-level de-rating could persist even with clean fundamentals
GLP-1 narrative overhang on insulin-delivery names could resurface on any positive obesity-drug data print
fwdPe 18.78 is reasonable but not cheap; PEG 0.81 leaves little margin if EPS growth of 18.77% is revised down
shortFloat 5.55% is modest but instOwn >100% (105.56) suggests crowded institutional positioning — forced unwinds can amplify downside

Honorable mentions

WMGCleanest 4-timeframe alignment in the pool (1h +15.3/+16.2, 4h +6.4/+13.6, 1d +16.6/+15.8, 1wk +18.5/+23.5), all positive; position at 0-17% of range across timeframes so no chasing; PEG 0.31, ROE 92.17, recent 'high-quality compounder' framing after Q3 beat. Slightly smaller forecast magnitudes than PODD, hence #2.

INTRDeep-value combo (fwdPe 5.12, peg 0.21) with monster 4h/1d forecasts (+63/+71/+79 and +16/+51/+50), position at 0-3% of range, record Q2 profitability just reported. Only knock is 1wk forecast is roughly flat and weekly downtrend of -34% is severe, so slightly less aligned than PODD/WMG.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	PODD	BUY NOW	8.8	All-timeframe positive forecasts (+45/+68% weekly, +62/+77% daily), low in range (7.5% wk), clean post-earnings analyst support.
2	WMG	BUY NOW	8.3	Rare 4-TF alignment on hourly/4h/daily/weekly, position 0-17% of range, PEG 0.31 and strong Q3.
3	INTR	BUY NOW	8.1	fwdPe 5.12/peg 0.21 with huge 4h/1d forecasts (+63-79%, +16-51%), position at 0-3% of range post record Q2.
4	HUBS	BUY PULLBACK	7.8	Huge weekly forecast (+80/+136%) and insider buying, but near-term 4h/1h forecasts modest and PE 74 leaves valuation risk.
5	ALNY	BUY NOW	7.5	PEG 0.29, sales +95%, EPS +52% next Y, 4h fc +46/+66/+72 and position at 3% of range — 'missed the mark' headline is a minor drag.
6	PDD	BUY NOW	7.4	PE 9.7, fwdPe 7.21, all TFs positive (+22/+22, +5/+20, +2/+28), clean tape and fresh Wasatch investment.
7	CALX	BUY PULLBACK	7.1	PEG 0.49, salesYoY 27.8%, but position at 100% of range on 4h/1d — chasing risk despite +34/+41 mid/long 4h fc.
8	APP	BUY PULLBACK	7.0	PEG 0.35, profitMargin 64.6%, RSI 26.6 oversold with strong 4h/1d fc, but 1wk fc -24/-73 and fresh 52-week-low headline argue for waiting.
9	ONON	BUY PULLBACK	6.8	Strong daily fc (+19/+31/+41) and position at 4% of range, but 'worst trading day ever' and Raymond James downgrade need to be digested.
10	NRG	BUY PULLBACK	6.7	peg 0.71 and strong 4h/1d fc, but 1wk fc -24/-34% and position at 3-13% suggest waiting for weekly to turn.
11	FUTU	BUY PULLBACK	6.6	Massive 4h fc (+46/+58/+55) and sales +52%, but position at 94% of range and 1wk fc -14/-23% flag chase risk.
12	INTU	BUY PULLBACK	6.5	fwdPe 12.21, huge 1d/1wk fc (+79/+54%), but at 100% of range on 1h and 1d — better entry on a pullback.
13	MIR	BUY PULLBACK	6.4	Strong near-term fc (4h +42/+35/+47, 1d +23/+40/+34) but 1wk fc negative and PE 172 makes valuation cushion thin.
14	ORCL	WAIT	6.2	Great fundamentals (ROE 54, profitMargin 25%), but all forecast horizons on 1wk are -6 to -10% and position at 78-97% of range.
15	FICO	BUY PULLBACK	6.1	Strong 4h/1d fc (+37/+24/+35, +10/+36/+42) with position at 2-4% of range, but UBS just cut PT and 1wk fc slightly negative.
16	BIRK	BUY PULLBACK	6.0	Fresh revenue beat and raised outlook is a positive catalyst, but 4h/1h at 100% of range and short-term fc -7/-9%.
17	KVYO	WAIT	5.9	Strong 4h fc (+22/+23/+45) and PEG 0.64, but PE 813, near_term_bullish 0, and margin outlook was cut post-earnings.
18	MNDY	BUY PULLBACK	5.8	Huge 1wk mid/long fc (+72/+111%), but hourly/4h fc are flat/negative and UBS/Citi both cut targets.
19	MLCO	WAIT	5.6	PE 9.47 and strong 1wk fc (+39/+47%), but near_term_bullish 0 and earnings still pending.
20	SGI	WAIT	5.5	Position at 11-14% of range with decent 4h/1d fc, but 1wk fc all negative (-4/-12/-18%) and Q2 missed on sales.
21	VERX	WAIT	5.3	4h/1d fc strong (+34/+43/+37 and +1/+37/+58), but PE 572, profitMargin 0.45%, near_term_bullish 0.
22	BILI	WAIT	5.2	Big 4h/1d fc (+33/+49/+58 and +26/+49/+38) but 1wk fc only +1.4/+3.7/+12.8 and salesYoY just 11.2%.
23	SRAD	AVOID	4.9	Cut 2026 outlook, UBS downgrade to Neutral — forecast strength offset by broken narrative.
24	OPFI	AVOID	4.7	Analysts cut forecasts after weak Q2, fair value falling — deep-value tape (peg 0.19) undermined by news.
25	AAON	WAIT	4.5	Position at 2-8% of range post -10% drop despite raised guidance; 1wk fc negative and daily near-term fc flat.
26	CRK	WAIT	4.3	Big 4h fc (+47/+46/+77) but weekly fc negative, shortFloat 31.7%, only 18% analyst upside.
27	PFSI	WAIT	4.2	Solid 4h/1d fc (+29/+42/+63 and +2/+30/+25) but analyst PT was just cut 13.6% and 'risky value' framing.
28	FRSH	AVOID	3.5	Every forecast horizon on every timeframe is negative (-16 to -20%), bullish_prob 0.2 despite decent fundamentals.
29	CCC	AVOID	3.2	RSI 73 overbought at 100% of range, 4h/1d fc all negative, bullish_prob 0.4.
30	QTWO	AVOID	2.9	Bullish_prob 0, at 98-100% of range across timeframes, all near-term fc negative.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord